Speaker: Prof.Benjamin G. Neel(Laura and Isaac Perlmutter Cancer Center,NYU)

Time: 10:00-12:00,Dec. 09,2019

Venue: Library 111 lecture hall

New combination therapies for cancer


Professor Benjamin G. Neel’s research focuses on cell signaling in cancer and developmental disease, as well as the biology of breast and ovarian cancer. In addition to authoring more than 200 original papers, 25 reviews, and 2 books, he has received multiple grants from the National Institutes of Health and National Cancer Institute, as well as private foundations. He was the inaugural recipient of the Gertrude Elion Award of the American Association for Cancer Research, has held multiple named lectureships, and serves on editorial board of several journals, including Cancer Cell, Molecular Cell, and Cancer Discovery, among others. He is an elected member of the Association of American Physicians, a former member of the board of directors of the American Association for Cancer Research, and co-founder of Northern Biologics, a biotechnology company developing new therapies for cancer and fibrosis.  


Selected Publications:

1.SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Model, Cancer Discov., 2018, 8, 1237-1249

2.Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression, Cell, 2017, 170, 1079-1095

3.Sticking It to Cancer with Molecular Glue for SHP2, Cancer Cell, 2016, 30194-196

4.Cancer: Bad neighbours cause bad blood, Nature, 2016:539(7628):173-175

5.Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signaling, Nature, 2013, 499, 491-495.

6.Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome“, Cell. 2011, 146, 826-840

7.Imaging Sites of Receptor Dephosphorylation by PTP1B on the Surface of the Endoplasmic Reticulum, Science, 2002, 295, 1708-1711

Next:Neuronal circuits in the hindbrain that control breathing and vocalization